Performance Chemicals grows 17% as EBIT nears breakeven Cost-savings programme successful, but still...
Media still growing ~20% organically despite a 'softer' quarter P&S weighing on revisions, but stron...
The McQuade Center for Strategic Research and Development (MSRD) has signed an exclusive R&D collabo...
Urstark rapport från bolaget… Omsättningen i kvartalet uppgick till EUR 28m, vilket motsvarar en til...
Recorded sales improved to SEK 17.9m (10.9m in Q4 and SEK 0m in Q1 2023), and the cash balance was ...
Redeye states that InfraCom's net sales was below expectations, and InfraCom states a tougher macro-...
Relais reported Q1 adjusted EBITA of EUR 9.7m, 13% above LSEG Data & Analytics consensus.
New dev collaboration with MSRD on IRL757 Seeking for a partner for mesdopetam's Ph 3 Webcast today ...
Investors House reported Q1 revenues of EUR 1.6m, 4% below our 1.
MODI reported sales growth in Q1’24 of 31%, confirming that the strong momentum seen in H2’23 carrie...
Fortsatt god tillväxt och lönsamhet Efter ett rekordstarkt 2023 med en tillväxt på 134% inledde Mave...
Redeye gives an initial take on the news that IRLAB has entered into a development cooperation with ...
Redeye comments on G5’s Q1-results where topline was softer than expected while solid profitability,...
Sales-2% and adj. EBITA +11% vs. ABGSCe Stunning 9.
Redeye updates on Nepa following the Q1 results which showed continued hesitation from clients hurti...
Redeye updates its estimates after reviewing Truecaller's Q1 report, which showed higher sales and p...
Redeye makes upward estimate revisions on the back of I-Tech’s solid Q1 figures.
Redeye provides an update following Optomed’s FDA clearance for Aurora AEYE and the company’s Q1 rep...
Taaleri's Q1 2024 results were well above LSEG Data & Analytics consensus and our expectations, driv...
NoHo Partners' Q1 2024 results were largely in line with Vara Research consensus expectations.
